GSK Plc is forecasting an increase in group turnover of 7% to 9% at constant exchange rates this year, but growth is expected to be powered by specialty medicines rather than vaccines. Vaccines for shingles and respiratory syncytial virus (RSV) put in a strong performance earlier this year but slumped in the third quarter following a raft of new regulatory measures.
The Roche Group expects to raise its dividend this year on the back of a recovery in sales led by strong demand for products treating multiple sclerosis, haemophilia A, and severe eye diseases. Group sales are expected to increase by a mid-single digit figure after rising by just 1% at constant exchange rates in 2023. The expected recovery reflects sales gains by newer products which are gradually offsetting the impact of competition from biosimilar versions of the company’s leading cancer medicines.
Agomab Therapeutics NV of Belgian has raised $89 million in new capital to advance a pipeline of candidate products for fibrotic disorders. Announced on 25 October, the Series D round brings total funds raised from investors to more than $320 million since the company’s launch in 2017. Based in Belgium, Agomab’s newest investors are Sanofi SA and Invus, a US private equity company. Existing investors include Fidelity Management & Research Co and EQT Life Sciences.
Research Strategy
A new cell reprogramming approach for cancer
By Cristiana Pires
Corporate Strategy
Isoform-specific antibody unlocks new pathway
By Jackie Turnbull
Oncology Review
Immunotherapies show positive data at ESMO
Regulation and Policy
EU guides on the use of AI in medicines regulation
Stock Market Performance
Europe's biotech sector enjoys better Q3
By Robin Davison
